公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | $4.4B | $4.3B | $4.4B | $4.5B | $4.6B | $4.5B | $3.2B | $3.5B | $3.3B | $2.8B | $2.4B | $2.2B | $1.9B | $1.4B | $1.1B | $1.1B | $903M | $666M | $573M | $367M | $185M |
| 売上総利益 | $2.9B | $2.9B | $2.9B | $2.7B | $3.0B | $3.2B | $2.2B | $2.5B | $2.3B | $1.8B | $1.7B | $1.5B | $1.3B | $912M | $774M | $709M | $602M | $461M | $368M | $234M | $125M |
| 売上総利益率 % | 67.1% | 66.7% | 65.4% | 60.9% | 64.8% | 69.7% | 68.0% | 69.6% | 69.0% | 66.3% | 69.5% | 69.8% | 69.7% | 64.2% | 67.3% | 67.2% | 66.6% | 69.1% | 64.1% | 63.9% | 67.8% |
| 営業利益（EBIT） | $919M | $864M | ($833M) | ($1.1B) | ($4.2B) | ($123M) | $393M | $985M | $883M | $606M | $587M | $613M | $515M | $134M | $201M | $199M | $212M | $126M | $80M | ($301M) | $38M |
| 営業利益率 % | 20.9% | 19.9% | -19.1% | -23.7% | -91.2% | -2.7% | 12.1% | 27.8% | 26.5% | 22.0% | 24.5% | 27.6% | 27.7% | 9.4% | 17.5% | 18.9% | 23.4% | 18.9% | 14.0% | -82.1% | 20.5% |
| 当期純利益 | $853M | $850M | ($1.2B) | ($1.2B) | ($4.4B) | $762M | $656M | $1.0B | $826M | $726M | $463M | $462M | $353M | $125M | $151M | $87M | $125M | $72M | $50M | ($278M) | $40M |
| 純利益率 % | 19.4% | 19.6% | -28.0% | -25.8% | -96.1% | 16.8% | 20.2% | 28.3% | 24.8% | 26.4% | 19.3% | 20.8% | 19.0% | 8.8% | 13.2% | 8.2% | 13.8% | 10.8% | 8.8% | -75.9% | 21.6% |
| EBITDA | $1.4B | $1.5B | ($725M) | ($1.1B) | ($3.8B) | $128M | $580M | $1.2B | $1.1B | $762M | $735M | $753M | $603M | $297M | $326M | $237M | $252M | $169M | $123M | $18M | $44M |
| 1株当たり利益（EPS） | $5.51 | $5.45 | $-7.69 | $-7.35 | $-28.05 | $5.05 | $4.43 | $6.72 | $5.54 | $4.91 | $3.13 | $3.10 | $2.37 | $0.90 | $1.13 | $0.62 | $0.87 | $0.53 | $0.38 | $-2.57 | $0.41 |
| 発行済株式数（百万株） | 154M | 156M | 159M | 158M | 157M | 151M | 148M | 149M | 149M | 148M | 148M | 149M | 149M | 140M | 134M | 139M | 143M | 137M | 134M | 108M | 98M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は ILMN のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/ILMN
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms